349 related articles for article (PubMed ID: 30726573)
1. Emerging links between pediatric lysosomal storage diseases and adult parkinsonism.
Ysselstein D; Shulman JM; Krainc D
Mov Disord; 2019 May; 34(5):614-624. PubMed ID: 30726573
[TBL] [Abstract][Full Text] [Related]
2. Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria.
Mechtler TP; Stary S; Metz TF; De Jesús VR; Greber-Platzer S; Pollak A; Herkner KR; Streubel B; Kasper DC
Lancet; 2012 Jan; 379(9813):335-41. PubMed ID: 22133539
[TBL] [Abstract][Full Text] [Related]
3. Pilot study of newborn screening for six lysosomal storage diseases using Tandem Mass Spectrometry.
Elliott S; Buroker N; Cournoyer JJ; Potier AM; Trometer JD; Elbin C; Schermer MJ; Kantola J; Boyce A; Turecek F; Gelb MH; Scott CR
Mol Genet Metab; 2016 Aug; 118(4):304-9. PubMed ID: 27238910
[TBL] [Abstract][Full Text] [Related]
4. Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease.
Robak LA; Jansen IE; van Rooij J; Uitterlinden AG; Kraaij R; Jankovic J; ; Heutink P; Shulman JM
Brain; 2017 Dec; 140(12):3191-3203. PubMed ID: 29140481
[TBL] [Abstract][Full Text] [Related]
5. Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond.
Shachar T; Lo Bianco C; Recchia A; Wiessner C; Raas-Rothschild A; Futerman AH
Mov Disord; 2011 Aug; 26(9):1593-604. PubMed ID: 21618611
[TBL] [Abstract][Full Text] [Related]
6. Basic findings and current developments in sphingolipidoses.
Pilz H; Heipertz R; Seidel D
Hum Genet; 1979 Mar; 47(2):113-34. PubMed ID: 108196
[TBL] [Abstract][Full Text] [Related]
7. [Recent advances in sphingolipidosis research].
Tamai Y; Kojima H
Tanpakushitsu Kakusan Koso; 1990 May; 35(7 Suppl):1291-303. PubMed ID: 1972585
[No Abstract] [Full Text] [Related]
8. Genetic convergence of Parkinson's disease and lysosomal storage disorders.
Deng H; Xiu X; Jankovic J
Mol Neurobiol; 2015; 51(3):1554-68. PubMed ID: 25099932
[TBL] [Abstract][Full Text] [Related]
9. Lysosomal defects in ATP13A2 and GBA associated familial Parkinson's disease.
Sato S; Li Y; Hattori N
J Neural Transm (Vienna); 2017 Nov; 124(11):1395-1400. PubMed ID: 28894968
[TBL] [Abstract][Full Text] [Related]
10. Niemann-Pick's and Gaucher's diseases.
Stern G
Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S143-6. PubMed ID: 24262167
[TBL] [Abstract][Full Text] [Related]
11. Hereditary Parkinsonism-Associated Genetic Variations in PARK9 Locus Lead to Functional Impairment of ATPase Type 13A2.
Park JS; Sue CM
Curr Protein Pept Sci; 2017; 18(7):725-732. PubMed ID: 26965689
[TBL] [Abstract][Full Text] [Related]
12. Lysosomal Storage of Subunit c of Mitochondrial ATP Synthase in Brain-Specific Atp13a2-Deficient Mice.
Sato S; Koike M; Funayama M; Ezaki J; Fukuda T; Ueno T; Uchiyama Y; Hattori N
Am J Pathol; 2016 Dec; 186(12):3074-3082. PubMed ID: 27770614
[TBL] [Abstract][Full Text] [Related]
13. Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis.
Bras J; Verloes A; Schneider SA; Mole SE; Guerreiro RJ
Hum Mol Genet; 2012 Jun; 21(12):2646-50. PubMed ID: 22388936
[TBL] [Abstract][Full Text] [Related]
14. Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease.
Wong YC; Krainc D
Mov Disord; 2016 Nov; 31(11):1610-1618. PubMed ID: 27619775
[TBL] [Abstract][Full Text] [Related]
15. Lysosomal storage disorders in Thailand: the Siriraj experience.
Wasant P; Wattanaweeradej S; Raksadawan N; Kolodny EH
Southeast Asian J Trop Med Public Health; 1995; 26 Suppl 1():54-8. PubMed ID: 8629143
[TBL] [Abstract][Full Text] [Related]
16. Lysosomal Proteins as a Therapeutic Target in Neurodegeneration.
Mc Donald JM; Krainc D
Annu Rev Med; 2017 Jan; 68():445-458. PubMed ID: 28099085
[TBL] [Abstract][Full Text] [Related]
17. Lysosomal Storage Disorders Shed Light on Lysosomal Dysfunction in Parkinson's Disease.
Blumenreich S; Barav OB; Jenkins BJ; Futerman AH
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32674335
[TBL] [Abstract][Full Text] [Related]
18. Polygenic Parkinson's Disease Genetic Risk Score as Risk Modifier of Parkinsonism in Gaucher Disease.
Blauwendraat C; Tayebi N; Woo EG; Lopez G; Fierro L; Toffoli M; Limbachiya N; Hughes D; Pitz V; Patel D; Vitale D; Koretsky MJ; Hernandez D; Real R; Alcalay RN; Nalls MA; Morris HR; Schapira AHV; Balwani M; Sidransky E
Mov Disord; 2023 May; 38(5):899-903. PubMed ID: 36869417
[TBL] [Abstract][Full Text] [Related]
19. Mutations in the ATP13A2 gene and Parkinsonism: a preliminary review.
Yang X; Xu Y
Biomed Res Int; 2014; 2014():371256. PubMed ID: 25197640
[TBL] [Abstract][Full Text] [Related]
20. The Parkinson-associated human P5B-ATPase ATP13A2 modifies lipid homeostasis.
Marcos AL; Corradi GR; Mazzitelli LR; Casali CI; Fernández Tome MDC; Adamo HP; de Tezanos Pinto F
Biochim Biophys Acta Biomembr; 2019 Oct; 1861(10):182993. PubMed ID: 31132336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
